Ariad Pharmaceuticals is re-launching its leukemia drug Iclusig (ponatinib) with new warnings about potential blood clots and the risk of heart failure. The Food and Drug Administration (FDA) ceased sales and promotion of the drug until the drug company addressed safety concerns including the danger of life-threatening blood clots associated with the medication. Iclusig is a treatment for two rare types of leukemia, chronic myeloid leukemia and acute myeloid leukemia. About 5,000 people are diagnosed with the chronic variety of the disease each year. Iclusig was approved by the FDA in late 2012 under the condition that it carry a ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.